B. Riley Lifts Earnings Estimates for KORU Medical Systems

KORU Medical Systems, Inc. (NASDAQ:KRMD) – B. Riley raised their FY2024 earnings per share (EPS) estimates for KORU Medical Systems in a research note issued to investors on Tuesday, January 14th. B. Riley analyst K. Bauser now anticipates that the company will post earnings per share of ($0.13) for the year, up from their prior forecast of ($0.14). The consensus estimate for KORU Medical Systems’ current full-year earnings is ($0.14) per share. B. Riley also issued estimates for KORU Medical Systems’ Q4 2024 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.09) EPS.

KRMD has been the topic of several other reports. Lake Street Capital upped their price objective on shares of KORU Medical Systems from $4.00 to $5.00 and gave the company a “buy” rating in a report on Tuesday. Piper Sandler raised their price objective on shares of KORU Medical Systems from $3.00 to $3.50 and gave the stock an “overweight” rating in a report on Thursday, November 14th. Canaccord Genuity Group boosted their target price on shares of KORU Medical Systems from $3.00 to $4.00 and gave the company a “buy” rating in a report on Thursday, November 14th. Finally, Craig Hallum increased their target price on KORU Medical Systems from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Friday. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, KORU Medical Systems presently has a consensus rating of “Buy” and an average price target of $4.50.

KORU Medical Systems Stock Up 2.3 %

KRMD stock opened at $4.09 on Thursday. The stock has a fifty day moving average of $3.80 and a 200-day moving average of $2.96. KORU Medical Systems has a fifty-two week low of $1.98 and a fifty-two week high of $4.60. The company has a market capitalization of $187.47 million, a price-to-earnings ratio of -16.36 and a beta of 0.45. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.37 and a current ratio of 2.99.

Institutional Trading of KORU Medical Systems

Hedge funds and other institutional investors have recently bought and sold shares of the company. XTX Topco Ltd purchased a new position in shares of KORU Medical Systems during the 3rd quarter valued at $34,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in KORU Medical Systems by 77.7% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 61,412 shares of the company’s stock valued at $168,000 after buying an additional 26,860 shares during the period. Geode Capital Management LLC boosted its stake in KORU Medical Systems by 6.5% during the third quarter. Geode Capital Management LLC now owns 462,128 shares of the company’s stock valued at $1,262,000 after buying an additional 28,323 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in KORU Medical Systems in the 2nd quarter worth about $107,000. Finally, Empire Financial Management Company LLC purchased a new stake in shares of KORU Medical Systems in the 3rd quarter valued at about $259,000. Institutional investors own 58.60% of the company’s stock.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria.